NEW YORK, May 25, 2018 (GLOBE NEWSWIRE) -- The study conducted by P&S Market Research analyzed that the restless leg syndrome therapeutics pipeline comprises of eight drug candidates in different stages of development.
Around 62% of the pipeline drug candidates are being developed as small molecule for the treatment of RLS. Hisamitsu Pharmaceutical Co., Inc. is in a process to conduct Phase III clinical trial on its developmental drug for the treatment of RLS. In September 2017, AXIM Biotechnologies Inc. announced that it was conducting Phase I and a proof of concept clinical trial (Phase II) of MedChew RL for treatment of RLS in Israel.
Request to get the sample page of the research report: https://www.psmarketresearch.com/market-analy...ort-sample
Various new technologies are being used by the companies for the development of drugs to treat RLS. For instance, Hisamitsu Pharmaceutical Co., Inc. is using Hisamitsu’s TDDS technology to deliver its developmental product ropinirole hydrochloride into the body through skin to maintain an adequate concentration in the blood for a long time and to avoid the first-pass effect in the liver. Alexza Pharmaceuticals Inc. is using its propriety staccato technology for the delivery of its development drug through inhalation.
The drugs candidates that are being developed by the different pharmaceutical companies have demonstrated positive clinical trial results which in-turn increase their further development. For instance, in April 2017, Merz Pharma GmbH & Co KgaA announced that incobotulinumtoxin demonstrated significant improvement of RLS score in the treatment of subjects with restless leg syndrome.
Browse report overview with detailed TOC on "Restless Legs Syndrome (RLS) Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments" at: https://www.psmarketresearch.com/market-analy...erapeutics
It has been observed that most of the drug candidates have received or have filed for patent covering a novel mechanism for the treatment of RLS. In April 2017, Omeros Corporation announced that it owned two issued patents and one pending patent application in the U.S., and 21 issued patents and 12 pending patent applications in foreign markets directed to its discoveries linking PDE7 Program - OMS527 to movement disorders. Patent approval help in increasing opportunities for invention improvement and uniqueness.
Some of the key players developing drugs for the treatment of restless leg syndrome include Hisamitsu Pharmaceutical Co., Inc., Merz Pharma GmbH & Co KgaA, AXIM Biotechnologies Inc., and Alexza Pharmaceuticals Inc.
mTOR Inhibitors Therapeutics - Pipeline Analysis 2017 - https://www.psmarketresearch.com/market-analy...erapeutics
Presbyopia Therapeutics - Pipeline Analysis 2018 - https://www.psmarketresearch.com/market-analy...e-analysis
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research-based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Contact: P&S Market Research
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
